• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease

Cryptococcal meningitis, the second-leading cause of HIV-related deaths, is expected to rise as access to care weakens and advanced HIV disease (previously called AIDS) increases

Home > Press releases

New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease

Cryptococcal meningitis, the second-leading cause of HIV-related deaths, is expected to rise as access to care weakens and advanced HIV disease (previously called AIDS) increases

Dar es Salaam / Lilongwe / Geneva — 15 Apr 2025

A new, easier-to-administer and patient-friendly sustained-release formulation of flucytosine, a medicine used to treat cryptococcal meningitis, has entered Phase II clinical trials in Malawi and Tanzania. The trial is being conducted by the not-for-profit research organization Drugs for Neglected Diseases initiative (DNDi) and its partners.  

‘As HIV funding cuts threaten to undo decades of progress in Africa, treatment interruptions are already threatening to push thousands into advanced HIV disease (AHD),’ said Dr Luis Pizarro, Executive Director of DNDi. ‘Essential AHD services have been disrupted, and stockouts of life-saving medicines like flucytosine are looming. Amidst this unprecedented crisis in multilateral cooperation, we must continue developing new treatment options for people living with HIV/AIDS and urgently strengthen international scientific collaborations.’ 

Cryptococcal meningitis is caused by the fungus Cryptococcus neoformans, found in soil and bird droppings, and is a major health threat to people with weakened immune systems. Those with advanced HIV are particularly at risk. It often begins with severe headaches, fever, nausea, and vomiting—progressing to neck stiffness, confusion, and, in late stages, coma due to inflammation of the brain and spinal cord. In Africa, where access to timely treatment is limited, the disease kills up to 70% of those who get it. 

‘When people with HIV can’t access effective treatment, they risk developing advanced HIV disease—and that opens the door to deadly infections like cryptococcal meningitis,’ said Dr Justine Odionyi, Head of HIV Disease at DNDi. ‘In 2023 alone, AIDS-related illnesses killed 390,000 people in Africa. Cryptococcal meningitis claimed 130,000 of those lives—deaths driven by treatment gaps. Now, with funding cuts, even more people will be left without care. More lives will be lost. It’s a terrifying reality.’ 

Lack of access to timely diagnosis and treatment is a major reason why cryptococcal meningitis remains so deadly. Across many countries, point-of-care CD4 testing—important for identifying people with advanced HIV—is in short supply. There are also growing shortages of cryptococcal antigen lateral flow assay (CrAg LFA) tests, which are recommended for routine screening in people living with HIV with low CD4 count. With fewer diagnostic tools available and a shrinking health workforce, linking patients to life-saving AHD care will become harder by the day. Unless urgent action is taken, continued disruptions to the AHD care package will result in hundreds of thousands of preventable deaths. 

Flucytosine, an effective and key component of the World Health Organization’s first-line treatment regimen for cryptococcal meningitis, is difficult to administer in overburdened, resource-limited settings. It must be taken every six hours, which can lead to missed doses. Additionally, many patients arrive at the hospital already in a coma, forcing healthcare staff to crush the tablets and administer them via nasogastric tube, a method not formally approved but often the only available option.

‘We were already struggling with limited supplies of flucytosine across many countries. Now, with the HIV funding cuts, the situation is becoming worse. Widespread stockouts are just around the corner. Without this life-saving drug, preventable deaths are inevitable,’ added Dr Odionyi.  

The open-label, randomized Phase II study for the new sustained-release flucytosine formulation will include 72 adult participants in Tanzania and Malawi. It simplifies dosing from four times to twice daily. It comes in pellet form, making it easier to take with water or through a nasogastric tube, and is suitable for outpatient self-administration. Participants will be divided into two groups: one will receive the current regimen of flucytosine every six hours for 14 days, while the other will receive the new sustained-release version—6000 mg taken twice daily. 

‘In 2023, around 12,000 people in Malawi died from AIDS-related illnesses. The need for faster diagnostic testing and simpler, more practical treatment options has never been more urgent,’ said Dr Cecilia Kanyama, Principal Investigator for the study at the University of North Carolina Project in Malawi. ‘The current flucytosine formulation is difficult to administer, which has impacted treatment outcomes for years. We’re hopeful this new formulation will be easier to use and lead to better outcomes for our patients.’  

‘In Tanzania, around 1.4 million people depend on antiretroviral therapy to manage HIV. We’ve been telling people HIV is no longer a death sentence—if you can access and stay on treatment,’ said Prof. Sayoki Mfinanga, Global Coordinating Investigator at the National Institute for Medical Research (NIMR) in Tanzania. ‘But with supply chains under threat, that progress is at risk. We urgently need innovative, simpler treatments to protect those with advanced HIV and stop unnecessary loss of life.’  

Donor and partner support

DNDi is developing the sustained-release flucytosine formulation in partnership with Mylan Laboratories Limited, India (a Viatris Company), the National Institute for Medical Research, Tanzania; University of North Carolina Project, Lilongwe, Malawi; Luxembourg Institute of Health; St George’s, University of London; and FARMOVS. The clinical trial is financially supported by the European and Developing Countries Clinical Trials Partnership Association (EDCTP2) programme supported by the European Union (grant RIA2018CO-2516), with funding from the UK National Institute for Health and Care Research. NIHR is funded by the Department of Health and Social Care. The NIHR Global Health Research portfolio supports high-quality applied health research for the direct and primary benefit of people in low and middle-income countries, using international development funding from the UK Government.

The trial is also supported by the Swiss Agency for Development and Cooperation (SDC), Switzerland; Médecins Sans Frontières International, and other private foundations and individuals.

About DNDi 

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected people. DNDi is developing medicines for sleeping sickness, leishmaniasis, Chagas disease, river blindness, mycetoma, dengue, paediatric HIV, advanced HIV disease, cryptococcal meningitis, and hepatitis C. Its research priorities include children’s health, gender equity and gender-responsive R&D, and diseases impacted by climate change. Since its creation in 2003, DNDi has joined with public and private partners across the globe to deliver 13 new treatments, saving millions of lives. 

Media contacts 

In Nairobi (DNDi Eastern Africa Office):
Edith Magak 
+254 780 86 20 49 
emagak@dndi.org 

In Geneva (DNDi Switzerland Office):
Frédéric Ojardias  
+41 79 431 62 16  
fojardias@dndi.org 

Photo credit: Linet Otieno Atieno-DNDi

Partnership Clinical trials Translational research Cryptococcal meningitis Africa

Read, watch, share

Loading...
Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License